ArticlePharmacology, biochemistry, and behavior2022
Age-related changes in CB1 receptor expression and function and the behavioral effects of cannabinoid receptor ligands.
Article in Pharmacology, biochemistry, and behavior, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Transcriptional and epigenetic regulation of the cannabinoid receptor type-1 (CB1R) in health and disease: an overview.Pharmacological reports : PR · 2026Review
- Increased Cannabinoid Receptor 1-Immunopositive Perisomatic Input of Principal Cells in Human Epileptic Patients in Focal Cortical Dysplasia Type IIB.International journal of molecular sciences · 2026Article
- β-caryophyllene, a CB2-selective phytocannabinoid, differentially modulates attention and inhibitory control in low- and high-performing young and aged mice.Psychopharmacology · 2026Article
- Memory impairment and chronic high-dose Δ9-THC/cannabis exposure: a narrative review of molecular mechanisms underlying neurotoxic effects.Psychopharmacology · 2026Review
- Epidemiology of Cannabis Use Among Middle-Aged and Older Adults in the U.S.American journal of preventive medicine · 2026Article
- Navigating dose-effect complexities and challenges in cannabinoid therapy for aging-related neurobiological changes.Frontiers in pharmacology · 2026Review
- Derivation of a health-based guidance value for ΔEFSA journal. European Food Safety Authority · 2025Article
- Recent Preclinical Evidence on Phytocannabinoids in Neurodegenerative Disorders: A Focus on Parkinson's and Alzheimer's Disease.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Blood oxygen regulation via P2Y12R expressed in the carotid body.Respiratory research · 2024Article
- Enhancing axonal myelination in seniors: A review exploring the potential impact cannabis has on myelination in the aged brain.Frontiers in aging neuroscience · 2023Review
- Cannabinoids in Late Life Parkinson's Disease and Dementia: Biological Pathways and Clinical Challenges.Brain sciences · 2022Review
- Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cannabinoid use has increased among aging individuals. However, little information on age-related differences in the behavioral effects of these agents is available. To explore potential differences in the behavioral effects of cannabinoids, we determined effects of Δ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.